Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 9/20 | 0.48 |
| ▸ | JAK3 | P52333 | 8/20 | 0.42 |
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | JAK1 | P23458 | 5/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616592 | 0.95 | ATR (0.47) | ATRJAK3JAK2JAK1ALOX5AP | |
| SCHEMBL16975964 | 0.92 | ATR (0.48) | ATRJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL14575196 | 0.89 | ATR (0.48) | ATRJAK3JAK2JAK1 | |
| SCHEMBL14575733 | 0.89 | ATR (0.47) | ATRJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL16975952 | 0.88 | JAK3 (0.51) | ATRJAK3JAK2JAK1SYK | |
| SCHEMBL14575472 | 0.84 | ATR (0.46) | ATRJAK3JAK2JAK1SYK | |
| SCHEMBL16975963 | 0.84 | ATR (0.43) | ATRJAK3JAK2JAK1SYK | |
| SCHEMBL14575236 | 0.84 | ATR (0.58) | ATRJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL14575683 | 0.84 | ATR (0.45) | ATRJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL14575093 | 0.84 | ATR (0.53) | ATRJAK3JAK2JAK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| US-20150376187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| US-9096602-B2 | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096602-B2 | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130017273-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130017273-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885JAK3 472/4885JAK2 281/4885 |
| US-20130017273-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885JAK3 472/4885JAK2 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.